Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Department of Medicine, University of Toronto, Toronto, ON, Canada; Division of Infectious Diseases, University Health Network, Toronto, ON, Canada.
Drug Alcohol Depend. 2018 Apr 1;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. Epub 2018 Feb 20.
Severe food insecurity (FI) is common among individuals living with HIV-hepatitis C virus (HCV) co-infection. We hypothesize that the injection of opioids is partly responsible for the association between injection drug use and severe FI. Therefore, this analysis examines whether methadone maintenance treatment for opioid dependence is associated with a lower risk of severe FI.
We used biannual data from the Canadian Co-infection Cohort (N = 608, 2012-2015). Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module. To quantify the association between methadone treatment and severe FI, we estimated an average treatment effect on the treated (marginal risk difference [RD]) using propensity score matching.
Among participants, 25% experienced severe FI in the six months preceding the first time-point in the analytical sample and 5% concurrently reported receiving methadone treatment. Injection of opioids in the six months preceding the treatment and outcome measurements was much higher among those who received methadone treatment (39% vs. 12%). Among the treated participants, 97% had injected opioids in their lifetimes. After propensity score matching, the average risk of experiencing severe FI is 12.3 percentage-points lower among those receiving methadone treatment, compared to those who are not receiving treatment (marginal RD = -0.123, 95% CI = -0.230, -0.015).
After adjustment for socioeconomic, sociodemographic, behavioural, and clinical confounders, methadone treatment is associated with a lower risk of severe FI. This finding suggests that methadone treatment may mitigate severe FI in this vulnerable subset of the HIV-positive population.
严重食物不安全(FI)在 HIV-丙型肝炎病毒(HCV)合并感染人群中很常见。我们假设注射阿片类药物是注射吸毒与严重 FI 之间关联的部分原因。因此,本分析检查了阿片类药物依赖的美沙酮维持治疗是否与严重 FI 的风险降低有关。
我们使用了加拿大合并感染队列(N=608,2012-2015 年)的每半年数据。美沙酮治疗(暴露)是自我报告的,严重 FI(结果)是使用家庭食物安全调查模块测量的。为了量化美沙酮治疗与严重 FI 之间的关联,我们使用倾向评分匹配估计了对治疗的平均治疗效果(边际风险差异[RD])。
在参与者中,25%的人在分析样本的第一次测量前的六个月内经历了严重 FI,5%的人同时报告接受了美沙酮治疗。在治疗和结果测量前的六个月内,接受美沙酮治疗的人注射阿片类药物的比例要高得多(39%比 12%)。在接受治疗的参与者中,97%的人在他们的一生中都注射过阿片类药物。经过倾向评分匹配后,与未接受治疗的参与者相比,接受美沙酮治疗的参与者经历严重 FI 的风险平均降低了 12.3 个百分点(边际 RD=-0.123,95%CI=-0.230,-0.015)。
在调整了社会经济、社会人口统计学、行为和临床混杂因素后,美沙酮治疗与严重 FI 的风险降低有关。这一发现表明,美沙酮治疗可能会减轻 HIV 阳性人群中这一脆弱亚群的严重 FI。